ArchiMed in talks to acquire Suanfarma for EUR 550m
ArchiMed negociaría la adquisición de Suanfarma por EUR 550m
Intel ID : 330764
|
||||
|
Intel ID | 330764 | |||
Value | EUR 550,00m (Approx.) | |||
Native Currency | Euro (EUR) | |||
Financial Data - Suanfarma
(31 Dec 2022) |
Revenue: EUR 92,43m EBITDA: EUR 1,97m Net Debt: EUR 722,88m People: 31 |
|||
Date |
![]() |
|||
Country | ![]() |
|||
Geography | ![]() |
|||
Subsector (Old TTR Sectors) |
|
|||
Type |
![]() |
|||
Intel Grade |
![]() |
|||
Source |
![]() |
|||
Tags | ![]() |
Bidder
Name |
|
||
Subsector (Old TTR Sectors) |
|
||
Primary Sector (TTRSC) |
25.01.09 Private Equity 25 Financial Services / 25.01 Banking & Investment |
||
Country |
![]() |
||
Website |
![]() |
||
Description |
![]() |
Target
Name |
|
||
Subsector (Old TTR Sectors) |
|
||
Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
Secondary Sectors (TTRSC) |
30.02.03 Healthcare Product Distributors 30 Healthcare / 30.02 Healthcare Equipment & Supplies |
||
Country |
![]() |
||
Website |
![]() |
||
Description |
![]() |
Seller
Name |
|
||
Subsector (Old TTR Sectors) |
|
||
Primary Sector (TTRSC) |
25.01.09 Private Equity 25 Financial Services / 25.01 Banking & Investment |
||
Country |
![]() |
||
Website |
![]() |
||
Description |
![]() |
Seller
Name |
|
||
Subsector (Old TTR Sectors) |
|
||
Primary Sector (TTRSC) |
25.01.09 Private Equity 25 Financial Services / 25.01 Banking & Investment |
||
Secondary Sectors (TTRSC) |
25.01.10 Venture Capital 25 Financial Services / 25.01 Banking & Investment |
||
Country |
![]() |
||
Website |
![]() |
||
Description |
![]() |
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.